Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data

Inclusion Criteria

• •General Cohort
• •Adult (18 years or older)
• •Newly initiating on Aimovig (no other claims during a 180-day wash-in period)
• •Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig through 180-days post-index
• •Primary \& Secondary Objectives Sub-Cohort
• •\- Had 3 consecutive months with a claim for Aimovig (≤15 days gap between days supply and the subsequent claim to be considered consecutive)
• •Primary \& Secondary Objectives Cost Sensitivity Analyses Sub-Cohorts
• •Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig through 270-days post-index to permit assessment of cost outcomes (all-cause and migraine-related) during days 91-270 post-index
• •Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig to the maximum follow-up time post-index with continuous medical and prescription insurance eligibility until the data end date (September 1, 2019)